Single-dose kinetics of primidone in acute viral hepatitis

F. Pisani, E. Perucca, G. Primerano, A. A. D'Agostino, R. M. Petrelli, A. Fazio, G. Oteri, R. Di Perri

Research output: Contribution to journalArticlepeer-review


The pharmacokinetics of primidone (PRM) after oral administration of a single 500 mg dose was studied in 7 patients with acute viral hepatitis and 7 healthy control subjects. The elimination half-life and the apparent clearance of unchanged PRM in the patients were 18.0±3.1 h and 42±14 ml·h-1·kg-1, respectively (mean ± SD) and did not differ significantly from the values in the controls (half-life 17.0±2.4 h; clearance 35±8 ml·h-1·kg-1). The metabolite phenylethylmalonamide (PEMA) was detected in the serum of all normal subjects within 2-24 h. By contrast, serum levels of this metabolite were undetectable (

Original languageEnglish
Pages (from-to)465-469
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Issue number4
Publication statusPublished - Jul 1984


  • primidone
  • primidone metabolism
  • single-dose kinetics
  • viral hepatitis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Single-dose kinetics of primidone in acute viral hepatitis'. Together they form a unique fingerprint.

Cite this